• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Predictions for the next 30 days





Don’t know much about Botox; but could they not just close the site and still keep the very small Botox group/lab open. That would certainly save a lot of money!!!


For one small building? Would that make sense? Still have operational costs for all the other buildings etc. Either Irvine becomes Allergan corporate again or it gets shut down. Many of the 3rd floor labs in the "New" Arnold R&D building have been eliminated or redesigned for other uses.
 
















Are who gonna get rid of all these useless Botox reps!?????? How many deadbeat reps are adding zero value and never leave their homes. AGN you are paying them salaries of 100 and 110 for noddin